Abstract

BIOEQUIVALENCE STUDY OF TWO APRAMYCIN FORMULATIONS (NEOVE APRAMYCIN SOLUBLE POWDER® AND APRABIOPHAR®) IN BROILER CHICKENS

Ashraf Elkomy* and Mohamed Aboubakr

ABSTRACT

The present study was designed to assess the comparative bio-equivalence of Neove Apramycin Soluble Powder® and Aprabiophar® in healthy broiler chicken after intramuscular injection (IM) of both products in a dose of 10 mg apramycin/kg b.wt. Twenty four broiler chickens were divided into two groups. The first group was designed to study the pharmacokinetics of Neove Apramycin Soluble Powder®, while the 2nd group was designed to study the pharmacokinetics of Aprabiophar®. Each broiler chicken in both groups was IM injected with 10 mg apramycin/kg b.wt. Blood samples were obtained from the wing vein and collected immediately before and at 0.08, 0.16, 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hours after a single IM injection. The disposition kinetics of Neove Apramycin Soluble Powder® and Aprabiophar® following IM injection of 10 mg apramycin /kg b.wt, revealed that the maximum blood concentration of apramycin [Cmax] were 9.95 and 9.67 μg/ml and attained at [tmax] of 2.33 and 2.35 hours, respectively. In conclusion: Aprabiophar® is bioequivalent to Neove Apramycin Soluble Powder® since the ratios of Cmax, AUC0-24 and AUC0-∞ (T/R) was 0.97, 0.96 and 0.96 respectively. These are within the bioequivalence acceptance range. Aprabiophar® and Neove Apramycin Soluble Powder® are therefore bioequivalent and interchangeable.

Keywords: .